AbbVie Inc. $ABBV Shares Acquired by Titleist Asset Management LLC

Titleist Asset Management LLC boosted its holdings in AbbVie Inc. (NYSE:ABBV) by 94.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,365 shares of the company’s stock after purchasing an additional 1,635 shares during the quarter. Titleist Asset Management LLC’s holdings in AbbVie were worth $625,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Nuveen LLC purchased a new stake in shares of AbbVie in the first quarter valued at about $1,819,154,000. Assenagon Asset Management S.A. increased its position in AbbVie by 550.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company’s stock valued at $804,116,000 after acquiring an additional 3,666,521 shares during the period. Goldman Sachs Group Inc. increased its position in AbbVie by 31.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 14,646,908 shares of the company’s stock valued at $3,068,820,000 after acquiring an additional 3,519,187 shares during the period. Vanguard Group Inc. raised its stake in AbbVie by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after acquiring an additional 3,380,842 shares during the last quarter. Finally, Kingstone Capital Partners Texas LLC acquired a new stake in AbbVie during the 2nd quarter worth approximately $581,817,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Trading Up 2.9%

NYSE:ABBV opened at $236.12 on Monday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The stock has a fifty day moving average price of $226.81 and a two-hundred day moving average price of $205.47. The stock has a market capitalization of $417.31 billion, a price-to-earnings ratio of 112.44, a PEG ratio of 1.42 and a beta of 0.50.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same period in the previous year, the firm earned $3.00 EPS. The business’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, sell-side analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 2.9%. AbbVie’s dividend payout ratio (DPR) is currently 524.24%.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ABBV. JPMorgan Chase & Co. boosted their target price on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. Piper Sandler reiterated an “overweight” rating and issued a $289.00 price objective (up from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Morgan Stanley boosted their price objective on shares of AbbVie from $250.00 to $255.00 and gave the company an “overweight” rating in a research note on Friday, August 1st. Guggenheim raised their target price on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research note on Monday, October 20th. Finally, Daiwa Capital Markets raised shares of AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 target price on the stock in a report on Thursday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $241.85.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.